Incidence, prevalence, and management of opioid bowel dysfunction (Q34470202)

2 August 2017

1 reference

title

Incidence, prevalence, and management of opioid bowel dysfunction (English)

1 reference

2 August 2017

0 references

M Pappagallo

1

1 reference

PubMed ID

11755892

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

The American Journal of Surgery

2 August 2017

1 reference

2 August 2017

182

1 reference

2 August 2017

5A Suppl

1 reference

2 August 2017

11S-18S

1 reference

Prevention of opioid side effects

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Effects on cancer patients' health-related quality of life after the start of morphine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

The relationship between opioid use and laxative use in terminally ill cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

The impact of home palliative care on symptoms in advanced cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Morphine, constipation and performance status in advanced cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Randomised trial of oral morphine for chronic non-cancer pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Opioid antagonists in the treatment of opioid-induced constipation and pruritus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Insights into opioid action in the intestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Constipation in advanced cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

The central and peripheral influences of opioids on gastrointestinal propulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Endogenous nitric oxide modulates morphine-induced constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Pharmacologic treatment of cancer pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

A volunteer model for the comparison of laxatives in opioid-related constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Assessment of nalmefene glucuronide as a selective gut opioid antagonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Oral naloxone reverses opioid-associated constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Treatment of opioid-induced constipation with oral naloxone: A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Gut motility and transit changes in patients receiving long-term methadone maintenance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Oral methylnaltrexone for opioid-induced constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900782-6

10.1016/S0002-9610(01)00782-6

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11755892